
Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment

2024 SV Therapeutics Impact & ESG Report
Read More

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System

SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise

Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure

Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More

SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion

Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics

SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner

Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership

Merck to Acquire Caraway Therapeutics, Inc.

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 5 December 2021SV NewsKate Bingham FT op-ed: Covid has given UK biotech a lesson — and a legacy
- 1 December 2021Portfolio NewsAviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform
- 29 November 2021Portfolio NewsQuell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform
- 23 November 2021Portfolio NewsLoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund
- 17 November 2021Portfolio NewsAlpheus Medical Closes $16M In Series A Financing For Novel Glioma Brain Cancer Treatment
- 10 November 2021Portfolio NewsSitryx appoints Tanya E. Borsuk, Ph.D., as Chief Business Officer
- 9 November 2021Portfolio NewsWelsh, Carson, Anderson & Stowe Acquires Majority Stake in Leiters
- 4 November 2021SV NewsVibrato Medical announced that Paul A. LaViolette has been appointed to its board of directors.
- 2 November 2021Portfolio NewsNitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics
- 29 October 2021Portfolio NewsBioventus Completes the Acquisition of Misonix
- 26 October 2021Portfolio NewsXilio Therapeutics Announces Closing of Initial Public Offering
- 21 October 2021Portfolio NewsZerigo Health Raises $43 Million in Series B Funding to Drive Adoption of the Industry’s Only Connected Light Therapy Solution to Treat Chronic Skin Conditions